Direvo: Cash in Agbio and Food Markets

Jörg Riesmeier, Direvo’s New COO describes near- to mid-term strategies

(C) Direvo 2010May 2010. After the bounty trade sale of Direvo’s pharmaceutical business line to Bayer Schering for €210m in 2008, investors hope to repeat such a profitable exit with remaining assets. Beginning 2010 shareholders pumped €6m into Direvo Industrial to bring them faster toward this goal. The firm’s pipeline offers attractive candidates, but will it have resources to turn these into products? Moreover, near-to-market developments have to be commercialised in agbio and food markets, both known not to lend itself to the pharma business model which management has successfully applied in the past.

Jörg Riesmeier is expected to manage transition and position Direvo in rather unfamiliar markets against established biotech suppliers. In an updated interview the new COO describes to B2Bioworld his near- and mid-term strategies. Included in-house comparisons by Direvo of mannanase and phytase competitor products.



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

exclusive interview, 4 pages

Go back

EXCLUSIVE STEM CELLS COLLECTION

Stem Cell Insights Collection 2010

Top 10 Tags

All Tags (2094)